Premium
Eosinophilic dermatosis of hematologic malignancy effectively controlled with omalizumab maintenance therapy
Author(s) -
Lor Michael,
Gates Gregory,
Yu Yang
Publication year - 2020
Publication title -
dermatologic therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.595
H-Index - 68
eISSN - 1529-8019
pISSN - 1396-0296
DOI - 10.1111/dth.14206
Subject(s) - omalizumab , medicine , dermatology , prednisone , rash , malignancy , maintenance therapy , eosinophilic , hematologic malignancy , surgery , chemotherapy , immunology , pathology , immunoglobulin e , antibody
Treatment of eosinophilic dermatosis of hematologic malignancy (EDHM) has been challenging with a minimal response to several modalities. Only systemic corticosteroids have consistently proven successful in suppressing the rash; however, the response is often only partial, and symptoms tend to recur as the dosage is tapered. This demonstrates the need for effective maintenance therapy. Herein, we present a case of EDHM that, following a 1 month prednisone taper and brief trial of narrow‐band ultraviolet B phototherapy, has remained well‐controlled with omalizumab. This suggests that omalizumab may represent an effective therapeutic alternative in EDHM management with low long‐term toxicity.